These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 15924505)

  • 41. A convenient in vitro screening method for predicting in vivo drug metabolic clearance using isolated hepatocytes suspended in serum.
    Shibata Y; Takahashi H; Ishii Y
    Drug Metab Dispos; 2000 Dec; 28(12):1518-23. PubMed ID: 11095592
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Consequences of renal insufficiency on the hepatic clearance of some drugs.
    Balant LP; Dayer P; Fabre J
    Int J Clin Pharmacol Res; 1983; 3(6):459-74. PubMed ID: 6147317
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance.
    Johnson TN; Boussery K; Rowland-Yeo K; Tucker GT; Rostami-Hodjegan A
    Clin Pharmacokinet; 2010 Mar; 49(3):189-206. PubMed ID: 20170207
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hepatic clearance of D-sorbitol. Noninvasive test for evaluating functional liver plasma flow.
    Molino G; Cavanna A; Avagnina P; Ballaré M; Torchio M
    Dig Dis Sci; 1987 Jul; 32(7):753-8. PubMed ID: 3595388
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships.
    Woodcock BG; Rietbrock I; Vöhringer HF; Rietbrock N
    Clin Pharmacol Ther; 1981 Jan; 29(1):27-34. PubMed ID: 7460471
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nabumetone (BRL 14777) presystemic elimination and disposition in patients with liver impairments.
    Terziivanov D; Maleev A; Vlahov V
    Int J Clin Pharmacol Ther Toxicol; 1987 Apr; 25(4):208-13. PubMed ID: 2884189
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide in patients with cirrhosis.
    Schwartz S; Brater DC; Pound D; Green PK; Kramer WG; Rudy D
    Clin Pharmacol Ther; 1993 Jul; 54(1):90-7. PubMed ID: 8330470
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of moderate or severe liver dysfunction on the pharmacokinetics of gamma-hydroxybutyric acid.
    Ferrara SD; Tedeschi L; Frison G; Orlando R; Mazzo M; Zordan R; Padrini R; Palatini P
    Eur J Clin Pharmacol; 1996; 50(4):305-10. PubMed ID: 8803524
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Renal effects of treatment with diuretics, octreotide or both, in non-azotemic cirrhotic patients with ascites.
    Kalambokis G; Economou M; Fotopoulos A; Bokharhii JA; Katsaraki A; Tsianos EV
    Nephrol Dial Transplant; 2005 Aug; 20(8):1623-9. PubMed ID: 15886218
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Theoretical considerations in the calculation of bioavailability of drugs exhibiting Michaelis-Menten elimination kinetics.
    Rubin GM; Tozer TN
    J Pharmacokinet Biopharm; 1984 Aug; 12(4):437-50. PubMed ID: 6527233
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Drug kinetics and alcohol ingestion.
    Sellers EM; Holloway MR
    Clin Pharmacokinet; 1978; 3(6):440-52. PubMed ID: 31257
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Influence of hepatic insufficiency in pharmacokinetics of drugs: example for an anthranilic diuretic.
    Dreux C; Passa P; Halter D
    Methods Find Exp Clin Pharmacol; 1979 Dec; 1(5):289-96. PubMed ID: 552592
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Theophylline pharmacokinetics in patients with liver diseases with reference to estimated hepatic blood flow].
    Nomura F; Ohnishi K; Ohto M; Takeda Y; Rikihisa T; Kanakubo Y
    Rinsho Byori; 1991 Oct; 39(10):1093-7. PubMed ID: 1762184
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Carbohydrate and lipid metabolism in cirrhosis. Evidence that hepatic uptake of gluconeogenic precursors and of free fatty acids depends on effective hepatic flow.
    Nosadini R; Avogaro A; Mollo F; Marescotti C; Tiengo A; Duner E; Merkel C; Gatta A; Zuin R; de Kreutzenberg S
    J Clin Endocrinol Metab; 1984 Jun; 58(6):1125-32. PubMed ID: 6373811
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Drug dosing adjustments in patients with chronic kidney disease.
    Munar MY; Singh H
    Am Fam Physician; 2007 May; 75(10):1487-96. PubMed ID: 17555141
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts.
    Chalasani N; Gorski JC; Patel NH; Hall SD; Galinsky RE
    Hepatology; 2001 Dec; 34(6):1103-8. PubMed ID: 11731998
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Oral V2 receptor antagonist (RWJ-351647) in patients with cirrhosis and ascites: a randomized, double-blind, placebo-controlled, single ascending dose study.
    Thuluvath PJ; Maheshwari A; Wong F; Yoo HW; Schrier RW; Parikh C; Steare S; Korula J
    Aliment Pharmacol Ther; 2006 Sep; 24(6):973-82. PubMed ID: 16948809
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetic study on the hepatic uptake of indocyanine green in cirrhotic patients.
    Kawasaki S; Sugiyama Y; Iga T; Hanano M; Sanjo K; Beppu T; Idezuki Y
    Am J Gastroenterol; 1985 Oct; 80(10):801-6. PubMed ID: 4036939
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of estimated glomerular filtration rate with estimated creatinine clearance in the dosing of drugs requiring adjustments in elderly patients with declining renal function.
    Spruill WJ; Wade WE; Cobb HH
    Am J Geriatr Pharmacother; 2008 Aug; 6(3):153-60. PubMed ID: 18775390
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment.
    Kearney BP; Yale K; Shah J; Zhong L; Flaherty JF
    Clin Pharmacokinet; 2006; 45(11):1115-24. PubMed ID: 17048975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.